Baidu
map

Ann Intern Med:HIV感染者的预期寿命可与正常未感染者接近

2016-11-16 xing.T MedSci原创

世界上许多地方的HIV感染者仍然不能获得最新的疗法所带来的好处。解决这些医疗护理的障碍是很重要,“因为这份以及其他类似的报告证明了其好处,我们可以期待在及时诊断、综合解决方案和新疗法方面的聚焦。”

只要有最佳的护理,感染HIV的个体其寿命可以接近未感染病毒的正常人,一个新的分析报告的作者说道。
 
“对于许多能够获得护理的HIV感染者,影响寿命和健康生活的主要障碍是生活方式因素,而与HIV病毒感染不直接相关。”Nicolai Lohse博士和Niels Obel博士,在11月15日发表于Annals of Internal Medicine杂志上的信函中写道。
 
这个结论来自于2007年作者对一项分析进行的更新,这项更新中揭示了25岁以下的年轻人感染了HIV病毒但不伴有丙型肝炎病毒(HCV)感染时,他们的中位生存年龄为63.9岁。虽然这些数据是“令人备受鼓舞的”,但是从一般人群中抽取的年龄和性别相匹配的样本,其中的研究对象预期寿命仍要短12.2年。
 
该项新分析的作者,均来自丹麦哥本哈根大学,估计了中位生存期在5个阶段过程中的变化,该5个阶段为:1995年–1996年,1997年–1999年,2000年–2004年,2005年–2009年和2010年–2015年。这项研究纳入了丹麦所有的HIV感染者,但不包括9.7%同时感染了HCV的患者。每个病人都从一般人群中匹配了五个年龄和性别相似的对照者。
 
在这项分析中包括了5701名HIV感染者和28,505名对照者,研究人员对HIV感染者共进行60,270人次每年的观察,对照组进行了365,713人次每年的观察。“这项研究包含77%的男性,参与者在进入研究之时的平均年龄为37.1岁(四分位间距为30.5–45.5岁),”作者写道。
 
在1995年-1996期间,25岁的HIV感染者估计的中位死亡年龄为34.5岁(95%可信区间为32.3-35.9岁)。在1997年-1999年期间,估计的中位死亡年龄上升到了52.2岁(95%可信区间为49-57.5岁);在2000年-2004年期间,估计的中位死亡年龄上升到62.8岁(95%可信区间为60.4-64.9岁);在2005年-2009年期间,估计的中位死亡年龄上升到66.8年(95%可信区间为65.7-68.5岁);在2010年-2015年期间,估计的中位死亡年龄上升到73.9年(95%可信区间为72.2-76.7岁)。作者将这些估计值与一般人群中的平均预期寿命80岁(95%可信区间为79.4-80.8岁)进行了比较。
 
作者总结认为,世界上许多地方的HIV感染者仍然不能获得最新的疗法所带来的好处。解决这些医疗护理的障碍是很重要,“因为这份以及其他类似的报告证明了其好处,我们可以期待在及时诊断、综合解决方案和新疗法方面的聚焦。”
 
原始出处:
 
1.Nicolai Lohse , et al. Update of Survival for Persons With HIV Infection in Denmark. Ann Intern Med. 2016;165:749-750
 
2.Norra MacReady. Life Expectancy With HIV Nears That of Uninfected Peers. Medscape Medical News. November 14, 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=157467, encodeId=12e215e467ff, content=生命在于质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161116/IMG582BD51C16DF04477.jpg, createdBy=e1401714907, createdName=1deb0fb2m59(暂无匿称), createdTime=Tue Nov 22 15:59:46 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290213, encodeId=fdeb12902135d, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315852, encodeId=4503131585215, content=<a href='/topic/show?id=bbc8100216a0' target=_blank style='color:#2F92EE;'>#预期寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100216, encryptionId=bbc8100216a0, topicName=预期寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607201, encodeId=dc4a160e20190, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156439, encodeId=b2fb15643906, content=期待进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 17 19:24:29 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156070, encodeId=d9581560e03c, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7feb1939351, createdName=fml857679646, createdTime=Wed Nov 16 09:43:03 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
    2016-11-22 1deb0fb2m59(暂无匿称)

    生命在于质量

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=157467, encodeId=12e215e467ff, content=生命在于质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161116/IMG582BD51C16DF04477.jpg, createdBy=e1401714907, createdName=1deb0fb2m59(暂无匿称), createdTime=Tue Nov 22 15:59:46 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290213, encodeId=fdeb12902135d, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315852, encodeId=4503131585215, content=<a href='/topic/show?id=bbc8100216a0' target=_blank style='color:#2F92EE;'>#预期寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100216, encryptionId=bbc8100216a0, topicName=预期寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607201, encodeId=dc4a160e20190, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156439, encodeId=b2fb15643906, content=期待进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 17 19:24:29 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156070, encodeId=d9581560e03c, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7feb1939351, createdName=fml857679646, createdTime=Wed Nov 16 09:43:03 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=157467, encodeId=12e215e467ff, content=生命在于质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161116/IMG582BD51C16DF04477.jpg, createdBy=e1401714907, createdName=1deb0fb2m59(暂无匿称), createdTime=Tue Nov 22 15:59:46 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290213, encodeId=fdeb12902135d, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315852, encodeId=4503131585215, content=<a href='/topic/show?id=bbc8100216a0' target=_blank style='color:#2F92EE;'>#预期寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100216, encryptionId=bbc8100216a0, topicName=预期寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607201, encodeId=dc4a160e20190, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156439, encodeId=b2fb15643906, content=期待进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 17 19:24:29 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156070, encodeId=d9581560e03c, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7feb1939351, createdName=fml857679646, createdTime=Wed Nov 16 09:43:03 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=157467, encodeId=12e215e467ff, content=生命在于质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161116/IMG582BD51C16DF04477.jpg, createdBy=e1401714907, createdName=1deb0fb2m59(暂无匿称), createdTime=Tue Nov 22 15:59:46 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290213, encodeId=fdeb12902135d, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315852, encodeId=4503131585215, content=<a href='/topic/show?id=bbc8100216a0' target=_blank style='color:#2F92EE;'>#预期寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100216, encryptionId=bbc8100216a0, topicName=预期寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607201, encodeId=dc4a160e20190, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156439, encodeId=b2fb15643906, content=期待进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 17 19:24:29 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156070, encodeId=d9581560e03c, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7feb1939351, createdName=fml857679646, createdTime=Wed Nov 16 09:43:03 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=157467, encodeId=12e215e467ff, content=生命在于质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161116/IMG582BD51C16DF04477.jpg, createdBy=e1401714907, createdName=1deb0fb2m59(暂无匿称), createdTime=Tue Nov 22 15:59:46 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290213, encodeId=fdeb12902135d, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315852, encodeId=4503131585215, content=<a href='/topic/show?id=bbc8100216a0' target=_blank style='color:#2F92EE;'>#预期寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100216, encryptionId=bbc8100216a0, topicName=预期寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607201, encodeId=dc4a160e20190, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156439, encodeId=b2fb15643906, content=期待进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 17 19:24:29 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156070, encodeId=d9581560e03c, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7feb1939351, createdName=fml857679646, createdTime=Wed Nov 16 09:43:03 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
    2016-11-17 studylzc

    期待进展。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=157467, encodeId=12e215e467ff, content=生命在于质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161116/IMG582BD51C16DF04477.jpg, createdBy=e1401714907, createdName=1deb0fb2m59(暂无匿称), createdTime=Tue Nov 22 15:59:46 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290213, encodeId=fdeb12902135d, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315852, encodeId=4503131585215, content=<a href='/topic/show?id=bbc8100216a0' target=_blank style='color:#2F92EE;'>#预期寿命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100216, encryptionId=bbc8100216a0, topicName=预期寿命)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607201, encodeId=dc4a160e20190, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 17 22:18:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156439, encodeId=b2fb15643906, content=期待进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 17 19:24:29 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156070, encodeId=d9581560e03c, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7feb1939351, createdName=fml857679646, createdTime=Wed Nov 16 09:43:03 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
    2016-11-16 fml857679646

    ?

    0

相关资讯

ID Week:ω-3脂肪酸可降低HIV患者的甘油三酯

根据呈现在IDWeek 2016的研究数据,对于感染HIV、稳定ART的患者,每日高剂量ω-3脂肪酸,与安慰剂相比,可降低患者的甘油三酯和C-反应蛋白水平。塔夫斯大学医学中心的Gretchen Volpe博士说,心血管疾病在艾滋病病毒感染者中普遍存在。“艾滋病毒通过多种途径增加心血管疾病,包括血脂异常、慢性炎症和血管功能障碍,”她在这里的一个演讲中说。Volpe及其同事进行了她所说的最长的随机对照

盘点:近期HIV重要研究一览

治愈HIV经常被称作HIV研究的最终梦想。虽然有效的抗HIV药物已经将艾滋病转变成了一种慢性可控的疾病,你可以携带着HIV一直生活,并且不会死于HIV感染,但终生治疗与完全治愈仍然存在很大不同,如果能找到一种既经济又能够规模化开展的HIV治愈方法,现在寻找HIV治愈方法的研究得到了越来越多的关注。这里小M整理了近期HIV亮点研究进展,与大家分享。【1】Nat Com:纳米医学方法可提高抗HIV

NEJM:利用抗体VRC01抑制感染者体内的HIV

在一项新的研究中,来自美国国家卫生研究院(NIH)、阿拉巴马大学伯明翰分校(UAB)和宾夕法尼亚大学宾州艾滋病研究中心的研究人员发现,在HIV-1感染者停止接受抗逆转录病毒疗法之后,服用一种强效的HIV特异性的广泛中和抗体是安全的和耐受良好的,产生较高的血浆抗体浓度,而且适度地延缓HIV病毒反弹。相关研究结果于2016年11月9日在线发表在New England Journal of Medici

Omega-3脂肪酸或可降低HIV患者心血管疾病的发病风险

据IDWeek 2016上一项新的研究展示表明,与安慰剂相比,接受抗逆转录病毒治疗稳定的HIV患者每日摄入较高水平的Omega-3脂肪酸可显著降低甘油三酯和C-反应蛋白的水平。HIV患者是心血管疾病的高危患者,该研究中,研究人员进行了一项随机对照试验以探究高剂量的ω-3脂肪酸在HIV患者中对血脂、炎症和血管功能的长期作用。研究共纳入了117名HIV感染者,均接受抗逆转录病毒治疗。随机分配分别每天接

J Hepatol:男男性接触的HIV患者中HCV的再感染率很高

在过去的十年中,男男性接触的HIV患者中,使用聚乙二醇干扰素和利巴韦林联合治疗急性丙型肝炎病毒感染的治愈率可达中等。然而,在已经清除病毒和对治疗有反应的男性中随后的HCV再感染发生率较高。采用回顾性分析探究来自奥地利、法国、德国和英国八个中心的男性HIV患者HCV的再感染率,时间为2002年5月至2014年6月。结果,606名自发清除HCV或治疗成功的患者中,149名(24.6%)患者出现了后续H

盘点:近期HIV研究进展汇总

治愈HIV经常被称作HIV研究的最终梦想。虽然有效的抗HIV药物已经将艾滋病转变成了一种慢性可控的疾病,你可以携带着HIV一直生活,并且不会死于HIV感染,但终生治疗与完全治愈仍然存在很大不同,如果能找到一种既经济又能够规模化开展的HIV治愈方法,现在寻找HIV治愈方法的研究得到了越来越多的关注。这里小M整理了近期脑卒中亮点研究进展及指南共识,与大家分享。【1】首例成功治癒的爱滋患者?英男体内

Baidu
map
Baidu
map
Baidu
map